^
Association details:
Biomarker:No biomarker
Cancer:Cutaneous Melanoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...the NCCN panel recommends pembrolizumab as an adjuvant therapy option for patients with stage III disease…Cutaneous melanoma.